222 related articles for article (PubMed ID: 12728404)
1. A clinical and scientific overview of tositumomab and iodine I 131 tositumomab.
Zelenetz AD
Semin Oncol; 2003 Apr; 30(2 Suppl 4):22-30. PubMed ID: 12728404
[TBL] [Abstract][Full Text] [Related]
2. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
BioDrugs; 2003; 17(4):290-5. PubMed ID: 12899647
[TBL] [Abstract][Full Text] [Related]
3. Bexxar: novel radioimmunotherapy for the treatment of low-grade and transformed low-grade non-Hodgkin's lymphoma.
Vose JM
Oncologist; 2004; 9(2):160-72. PubMed ID: 15047920
[TBL] [Abstract][Full Text] [Related]
4. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.
Vose JM; Wahl RL; Saleh M; Rohatiner AZ; Knox SJ; Radford JA; Zelenetz AD; Tidmarsh GF; Stagg RJ; Kaminski MS
J Clin Oncol; 2000 Mar; 18(6):1316-23. PubMed ID: 10715303
[TBL] [Abstract][Full Text] [Related]
5. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.
Fisher RI; Kaminski MS; Wahl RL; Knox SJ; Zelenetz AD; Vose JM; Leonard JP; Kroll S; Goldsmith SJ; Coleman M
J Clin Oncol; 2005 Oct; 23(30):7565-73. PubMed ID: 16186600
[TBL] [Abstract][Full Text] [Related]
6. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.
Friedberg JW; Fisher RI
Expert Rev Anticancer Ther; 2004 Feb; 4(1):18-26. PubMed ID: 14748653
[TBL] [Abstract][Full Text] [Related]
7. Development of 131I-tositumomab.
Lewington V
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S50-6. PubMed ID: 15786026
[TBL] [Abstract][Full Text] [Related]
8. Establishing an institutional model for the administration of tositumomab and iodine I 131 tositumomab.
Hohenstein MA; Augustine SC; Rutar F; Vose JM
Semin Oncol; 2003 Apr; 30(2 Suppl 4):39-49. PubMed ID: 12728406
[TBL] [Abstract][Full Text] [Related]
9. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.
Kaminski MS; Zelenetz AD; Press OW; Saleh M; Leonard J; Fehrenbacher L; Lister TA; Stagg RJ; Tidmarsh GF; Kroll S; Wahl RL; Knox SJ; Vose JM
J Clin Oncol; 2001 Oct; 19(19):3918-28. PubMed ID: 11579112
[TBL] [Abstract][Full Text] [Related]
10. The clinical importance of dosimetry in radioimmunotherapy with tositumomab and iodine I 131 tositumomab.
Wahl RL
Semin Oncol; 2003 Apr; 30(2 Suppl 4):31-8. PubMed ID: 12728405
[TBL] [Abstract][Full Text] [Related]
11. Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement.
Mones JV; Coleman M; Kostakoglu L; Furman RR; Chadburn A; Shore TB; Muss D; Stewart P; Kroll S; Vallabhajosula S; Goldsmith SJ; Leonard JP
Leuk Lymphoma; 2007 Feb; 48(2):342-8. PubMed ID: 17325895
[TBL] [Abstract][Full Text] [Related]
12. The radioisotope contributes significantly to the activity of radioimmunotherapy.
Davis TA; Kaminski MS; Leonard JP; Hsu FJ; Wilkinson M; Zelenetz A; Wahl RL; Kroll S; Coleman M; Goris M; Levy R; Knox SJ
Clin Cancer Res; 2004 Dec; 10(23):7792-8. PubMed ID: 15585610
[TBL] [Abstract][Full Text] [Related]
13. Iodine 131 tositumomab in the treatment of non-Hodgkin's lymphoma.
Smith S; Sweetenham JW
Future Oncol; 2007 Jun; 3(3):255-62. PubMed ID: 17547519
[TBL] [Abstract][Full Text] [Related]
14. Targeted radio-immunotherapy with Bexxar produces durable remissions in patients with late stage low grade non-Hodgkin's lymphomas.
Capizzi RL
Trans Am Clin Climatol Assoc; 2004; 115():255-72. PubMed ID: 17060972
[TBL] [Abstract][Full Text] [Related]
15. High-dose [131I]tositumomab (anti-CD20) radioimmunotherapy and autologous hematopoietic stem-cell transplantation for adults > or = 60 years old with relapsed or refractory B-cell lymphoma.
Gopal AK; Rajendran JG; Gooley TA; Pagel JM; Fisher DR; Petersdorf SH; Maloney DG; Eary JF; Appelbaum FR; Press OW
J Clin Oncol; 2007 Apr; 25(11):1396-402. PubMed ID: 17312330
[TBL] [Abstract][Full Text] [Related]
16. Tositumomab and (131)I therapy in non-Hodgkin's lymphoma.
Wahl RL
J Nucl Med; 2005 Jan; 46 Suppl 1():128S-40S. PubMed ID: 15653661
[TBL] [Abstract][Full Text] [Related]
17. Radioimmunotherapy with tositumomab and iodine-131 tositumomab for low-grade non-Hodgkin lymphoma: nursing implications.
Estes JM; Clapp KJ
Oncol Nurs Forum; 2004 Nov; 31(6):1119-26. PubMed ID: 15547634
[TBL] [Abstract][Full Text] [Related]
18. Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.
Kaminski MS; Radford JA; Gregory SA; Leonard JP; Knox SJ; Kroll S; Wahl RL
J Clin Oncol; 2005 Nov; 23(31):7985-93. PubMed ID: 16204016
[TBL] [Abstract][Full Text] [Related]
19. Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.
Davies AJ; Rohatiner AZ; Howell S; Britton KE; Owens SE; Micallef IN; Deakin DP; Carrington BM; Lawrance JA; Vinnicombe S; Mather SJ; Clayton J; Foley R; Jan H; Kroll S; Harris M; Amess J; Norton AJ; Lister TA; Radford JA
J Clin Oncol; 2004 Apr; 22(8):1469-79. PubMed ID: 15084620
[TBL] [Abstract][Full Text] [Related]
20. Outpatient radioimmunotherapy with Bexxar. Closed, clean air reservoir minimizes personnel radiation exposure.
Harwood SJ; Gibbons LK; Goldner PJ; Webster WB; Carroll RG
Cancer; 2002 Feb; 94(4 Suppl):1358-62. PubMed ID: 11877766
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]